These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 24652495)

  • 1. Long-term effect of depot medroxyprogesterone acetate on vaginal microbiota, epithelial thickness and HIV target cells.
    Mitchell CM; McLemore L; Westerberg K; Astronomo R; Smythe K; Gardella C; Mack M; Magaret A; Patton D; Agnew K; McElrath MJ; Hladik F; Eschenbach D
    J Infect Dis; 2014 Aug; 210(4):651-5. PubMed ID: 24652495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genital Injury Signatures and Microbiome Alterations Associated With Depot Medroxyprogesterone Acetate Usage and Intravaginal Drying Practices.
    Birse KD; Romas LM; Guthrie BL; Nilsson P; Bosire R; Kiarie J; Farquhar C; Broliden K; Burgener AD
    J Infect Dis; 2017 Feb; 215(4):590-598. PubMed ID: 28011908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Effect of Hormonal Contraception on Cervicovaginal Mucosal End Points Associated with HIV Acquisition.
    Thurman A; Chandra N; Schwartz JL; Brache V; Chen BA; Asin S; Rollenhagen C; Herold BC; Fichorova RN; Hillier SL; Weiner DH; Mauck C; Doncel GF
    AIDS Res Hum Retroviruses; 2019 Sep; 35(9):853-864. PubMed ID: 30997816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Depot medroxyprogesterone acetate increases immune cell numbers and activation markers in human vaginal mucosal tissues.
    Chandra N; Thurman AR; Anderson S; Cunningham TD; Yousefieh N; Mauck C; Doncel GF
    AIDS Res Hum Retroviruses; 2013 Mar; 29(3):592-601. PubMed ID: 23189932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human vaginal histology in long-term users of the injectable contraceptive depot-medroxyprogesterone acetate.
    Bahamondes MV; Castro S; Marchi NM; Marcovici M; Andrade LA; Fernandes A; Bahamondes L
    Contraception; 2014 Aug; 90(2):117-22. PubMed ID: 24613369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medroxyprogesterone acetate alters the vaginal microbiota and microenvironment in women and increases susceptibility to HIV-1 in humanized mice.
    Wessels JM; Lajoie J; Cooper MIJH; Omollo K; Felker AM; Vitali D; Dupont HA; Nguyen PV; Mueller K; Vahedi F; Kimani J; Oyugi J; Cheruiyot J; Mungai JN; Deshiere A; Tremblay MJ; Mazzulli T; Stearns JC; Ashkar AA; Fowke KR; Surette MG; Kaushic C
    Dis Model Mech; 2019 Oct; 12(10):. PubMed ID: 31537512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Research gaps in defining the biological link between HIV risk and hormonal contraception.
    Murphy K; Irvin SC; Herold BC
    Am J Reprod Immunol; 2014 Aug; 72(2):228-35. PubMed ID: 24548147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential effects of depot medroxyprogesterone acetate administration on vaginal microbiome in Hispanic White and Black women.
    Yang L; Hao Y; Hu J; Kelly D; Li H; Brown S; Tasker C; Roche NE; Chang TL; Pei Z
    Emerg Microbes Infect; 2019; 8(1):197-210. PubMed ID: 30866773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of contraceptive depot medroxyprogesterone acetate is associated with impaired cervicovaginal mucosal integrity.
    Zalenskaya IA; Chandra N; Yousefieh N; Fang X; Adedipe OE; Jackson SS; Anderson SM; Mauck CK; Schwartz JL; Thurman AR; Doncel GF
    J Clin Invest; 2018 Oct; 128(10):4622-4638. PubMed ID: 30222141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An updated review on the effects of depot medroxyprogesterone acetate on the mucosal biology of the female genital tract.
    Ayele H; Perner M; McKinnon LR; Birse K; Farr Zuend C; Burgener A
    Am J Reprod Immunol; 2021 Sep; 86(3):e13455. PubMed ID: 33991137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progestin-based contraception regimens modulate expression of putative HIV risk factors in the vaginal epithelium of pig-tailed Macaques.
    Bosinger SE; Tharp GK; Patel NB; Zhao C; Payne TL; Dietz Ostergaard S; Butler K; Ellis S; Johnson RL; Kersh EN; McNicholl JM; Vishwanathan SA
    Am J Reprod Immunol; 2018 Oct; 80(4):e13029. PubMed ID: 30076667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in Vaginal Microbiota and Immune Mediators in HIV-1-Seronegative Kenyan Women Initiating Depot Medroxyprogesterone Acetate.
    Roxby AC; Fredricks DN; Odem-Davis K; Ásbjörnsdóttir K; Masese L; Fiedler TL; De Rosa S; Jaoko W; Kiarie JN; Overbaugh J; McClelland RS
    J Acquir Immune Defic Syndr; 2016 Apr; 71(4):359-66. PubMed ID: 26914908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physiologic doses of depot-medroxyprogesterone acetate do not increase acute plasma simian HIV viremia or mucosal virus shedding in pigtail macaques.
    Radzio J; Hanley K; Mitchell J; Ellis S; Deyounks F; Jenkins LT; Hanson D; Heneine W; García-Lerma JG
    AIDS; 2014 Jun; 28(10):1431-9. PubMed ID: 24759208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of progestin-based contraceptives on HIV-associated vaginal immune biomarkers and microbiome in adolescent girls.
    Nasr MA; Aldous A; Daniels J; Joy C; Capozzi E; Yang M; Moriarty P; Emmanuel-Baker V; Malcolm S; Green SJ; Gomez-Lobo V; Ghosh M
    PLoS One; 2024; 19(7):e0306237. PubMed ID: 39008499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Depot medroxyprogesterone acetate (DMPA) enhances susceptibility and increases the window of vulnerability to HIV-1 in humanized mice.
    Wessels JM; Nguyen PV; Vitali D; Mueller K; Vahedi F; Felker AM; Dupont HA; Bagri P; Verschoor CP; Deshiere A; Mazzulli T; Tremblay MJ; Ashkar AA; Kaushic C
    Sci Rep; 2021 Feb; 11(1):3894. PubMed ID: 33594113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased Cervical CD4
    Lajoie J; Tjernlund A; Omollo K; Edfeldt G; Röhl M; Boily-Larouche G; Cheruiyot J; Kimani M; Kimani J; Oyugi J; Broliden K; Fowke KR
    AIDS Res Hum Retroviruses; 2019 Mar; 35(3):236-246. PubMed ID: 30585733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hormonal contraception and HIV-1 infection: medroxyprogesterone acetate suppresses innate and adaptive immune mechanisms.
    Huijbregts RP; Helton ES; Michel KG; Sabbaj S; Richter HE; Goepfert PA; Hel Z
    Endocrinology; 2013 Mar; 154(3):1282-95. PubMed ID: 23354099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medroxyprogesterone acetate and levonorgestrel increase genital mucosal permeability and enhance susceptibility to genital herpes simplex virus type 2 infection.
    Quispe Calla NE; Vicetti Miguel RD; Boyaka PN; Hall-Stoodley L; Kaur B; Trout W; Pavelko SD; Cherpes TL
    Mucosal Immunol; 2016 Nov; 9(6):1571-1583. PubMed ID: 27007679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of combined oral contraceptives, depot medroxyprogesterone acetate and the levonorgestrel-releasing intrauterine system on the vaginal microbiome.
    Brooks JP; Edwards DJ; Blithe DL; Fettweis JM; Serrano MG; Sheth NU; Strauss JF; Buck GA; Jefferson KK
    Contraception; 2017 Apr; 95(4):405-413. PubMed ID: 27913230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential Elevation of Inflammation and CD4
    Omollo K; Lajoie J; Oyugi J; Wessels JM; Mwaengo D; Kimani J; Kaushic C; Fowke KR
    Front Immunol; 2020; 11():598307. PubMed ID: 33717049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.